Plasma copeptin, kidney outcomes, ischemic heart disease, and all-cause mortality in people with long-standing type 1 diabetes

Diabetes Care

Volumn 39, Issue 12, 2016, Pages 2288-2295

  Velho, Gilberto ^a   El Boustany, Ray ^a   Lefèvre, Guillaume ^b   Mohammedi, Kamel ^a,c   Fumeron, Frédéric ^a,d   Potier, Louis ^a,c,d   Bankir, Lise ^a,e   Bouby, Nadine ^a,e   Hadjadj, Samy ^f,g,h   Marre, Michel ^a,c,d   Roussel, Ronan ^a,c,d  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f POITIERS UNIVERSITY HOSPITAL   (France)

^g INSERM   (France)

^h UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; COPEPTIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; VASOPRESSIN; GLYCOPEPTIDE;

ADOLESCENT; ALBUMINURIA; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA OSMOLALITY; SYSTOLIC BLOOD PRESSURE; ADULT; BLOOD; COMPLICATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE COURSE; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROGNOSIS; TIME FACTOR;

ADULT; ALBUMINURIA; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLYCOPEPTIDES; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROGNOSIS; TIME FACTORS;

EID: 85006160303     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-1003     Document Type: Article

References (40)

1. Bankir L, Bardoux P, Ahloulay M. Vasopressin and diabetes mellitus. Nephron 2001;87:8-18
2. Zerbe RL, Vinicor F, Robertson GL. Regulation of plasma vasopressin in insulin-dependent diabetes mellitus. Am J Physiol 1985;249:E317-E325
3. Taveau C, Chollet C, Waeckel L, et al. Vasopressin and hydration play a major role in the development of glucose intolerance and hepatic steatosis in obese rats. Diabetologia 2015;58: 1081-1090
4. Bankir L, Bouby N, Ritz E. Vasopressin: A novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 2013;9:223-239
5. Wang CJ, Grantham JJ,Wetmore JB. The medicinal use of water in renal disease. Kidney Int 2013;84:45-53
6. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 2008;371:1624-1632
7. Balanescu S, Kopp P, GaskillMB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states. J Clin Endocrinol Metab 2011;96:1046-1052
8. Roussel R, Fezeu L, Marre M, et al. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab 2014;99:4656-4663
9. Saleem U, Khaleghi M, Morgenthaler NG, et al. Plasma carboxy-terminal provasopressin (copeptin): A novel marker of insulin resistance and metabolic syndrome. J Clin Endocrinol Metab 2009;94:2558-2564
10. Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010;121:2102-2108
11. Abbasi A, Corpeleijn E, Meijer E, et al. Sex differences in the association between plasma copeptin and incident type 2 diabetes: The Prevention of Renal and Vascular Endstage Disease (PREVEND) study. Diabetologia 2012;55:1963-1970
12. Enhorning S, Bankir L, Bouby N, et al. Copeptin, amarker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: The prospective Malmö Diet and Cancer Study cardiovascular cohort. Int J Obes 2013;37:598-603
13. Then C, Kowall B, Lechner A, et al. Plasma copeptin is associated with type 2 diabetes in men but not in women in the population-based KORA F4 study. Acta Diabetol 2015;52:103-112
14. Roussel R, El Boustany R, Bouby N, et al. Plasma copeptin, AVP gene variants, and incidence of type 2 diabetes in a cohort from the community. J Clin Endocrinol Metab 2016;101: 2432-2439
15. Ponte B, Pruijm M, Ackermann D, et al. Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study. J Am Soc Nephrol 2015;26:1415-1425
16. Roussel R, Matallah N, Bouby N, et al. Plasma copeptin and decline in renal function in a cohort from the community: The prospective D.E.S.I.R. study. AmJ Nephrol 2015;42:107-114
17. Pikkemaat M, Melander O, Bengtsson Boström K. Association between copeptin and declining glomerular filtration rate in people with newly diagnosed diabetes. The Skaraborg Diabetes Register. J Diabetes Complications 2015;29:1062-1065
18. Velho G, Bouby N, Hadjadj S, et al. Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 2013;36:3639-3645
19. Marre M, Jeunemaitre X, Gallois Y, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 1997;99:1585-1595
20. Hadjadj S, Péan F, Gallois Y, et al.; Genesis France-Belgium Study. Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: The Genesis France-Belgium Study. Diabetes Care 2004;27:2661-2668
21. Kohner EM. The lesions and natural history of diabetic retinopathy. In Textbook of Diabetes. Pickup J, Williams G, Eds. Oxford, Blackwell Scientific, 1991, p. 575-588
22. Patente TA, Mohammedi K, Bellili-Munoz N, et al. Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes. Free Radic Biol Med 2015;86:16-24
23. Mohammedi K, Bellili-Munoz N, Marklund SL, et al. Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes. Cardiovasc Diabetol 2015; 14:845
24. Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009;94:123-129
25. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010;77:29-36
26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999;130:461-470
27. Bjornstad P, Maahs DM, Jensen T, et al. Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes. J Diabetes Complications 2016; 30:1093-1096
28. Meijer E, Bakker SJ, van der Jagt EJ, et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:361-368
29. Boertien WE, Meijer E, Li J, et al.; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 2013;61:420-429
30. Torres VE, Chapman AB, Devuyst O, et al.; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-2418
31. Meijer E, Bakker SJ, de Jong PE, et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009;88:561-567
32. Enhorning S, Hedblad B, Nilsson PM, Engstrom G, Melander O: Copeptin is an independent predictor of diabetic heart disease and death. Am Heart J 2015;169:549-556
33. Tasevska I, Enhörning S, Persson M, Nilsson PM, Melander O. Copeptin predicts coronary artery disease cardiovascular and total mortality. Heart 2016;102:127-132
34. Fenske W, Wanner C, Allolio B, et al.; German Diabetes, Dialysis Study Investigators. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J AmSoc Nephrol 2011;22:782-790
35. Koshimizu TA, Nakamura K, Egashira N, HiroyamaM, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev 2012;92: 1813-1864
36. Abu-Basha EA, Yibchok-Anun S, Hsu WH. Glucose dependency of arginine vasopressininduced insulin and glucagon release from the perfused rat pancreas. Metabolism 2002;51: 1184-1190
37. Bouby N, Bachmann S, Bichet D, Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990;258:F973-F979
38. Bouby N, Hassler C, Bankir L. Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci 1999; 65:991-1004
39. Groop PH, Thomas MC, Moran JL, et al.; FinnDiane Study Group. The presence and severity of chronic kidney disease predicts allcause mortality in type 1 diabetes. Diabetes 2009;58:1651-1658
40. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014;371:1972-1982